A P Giannini Foundation

The A.P. Giannini Foundation operates with an unusually narrow and well-defined giving philosophy: since its founding by Bank of America pioneer A.P. Giannini in 1945, every dollar of fellowship funding has flowed to postdoctoral biomedical researchers at California's accredited medical schools. There are no general operating grants, no capital campaigns, and no exceptions for out-of-state institutions. This laser focus means the Foundation is not a broad philanthropy prospect — it is exclusively a talent-investing vehicle, backing early-career researchers it believes will become the next generation of scientific leaders.

The giving model is strictly individual-driven. Grants go directly to the host institution as salary support for a named postdoctoral fellow, not to institutional research programs. This matters structurally because the application is entirely the fellow's own — this is not a standard "organization applies for program funding" model. Institutions cannot submit on behalf of candidates; the postdoc assembles and submits independently through an online portal (my.reviewr.com).

There is no letter of inquiry stage and no pre-proposal. The Foundation runs a single annual cycle with a hard November deadline (typically the first week of November, 3:00 PM PST). All materials — including the mentor's letter and three reference letters — must be submitted through the portal by that same deadline. No exceptions for late submissions or alternate formats are made.

First-time applicants must understand that the Scientific Advisory Committee evaluates four criteria with equal weight: the candidate's academic record and potential, the scientific innovation and medical significance of the proposed research, the quality of mentorship, and the candidate's leadership development plan. The Foundation's identity as a 'Leadership Award' — not merely a research stipend — means candidates who show strong science without a credible plan to become scientific leaders are unlikely to advance. The March finalist interview at Pebble Beach, CA, is a central feature of the process, allowing the board and scientific committee to assess communication skill and leadership vision directly.

Since 1951, the Foundation has funded over 700 fellows — roughly 6 to 8 per year — and has distributed nearly $50 million. The acceptance rate is below 20%, placing it in the category of elite postdoctoral fellowships. Stanford University School of Medicine has historically received the largest share of fellowships, followed by UCSF, UC San Diego, and UCLA.

The A.P. Giannini Foundation's financial profile reflects a well-managed endowment with total assets of approximately $26.5 million as of fiscal year 2023 (rising to a reported $30 million in the most recent filing). Annual total giving has ranged from $1.26 million (2013) to $1.84 million (2022) over the past decade, with recent years clustering around $1.5–1.6 million. The 2023 fiscal year recorded total giving of $1.63 million against grants paid of $1.02 million — the gap reflects multi-year fellowship commitments, which spread a single three-year award across annual payments to the host institution.

Individual fellowship stipends have grown substantially. The Foundation's FAQ (reflecting 2012 figures) listed Year 1 at $43,000, Year 2 at $44,000, and Year 3 at $46,000, plus a one-time $2,000 relocation allowance. By the 2026 cycle, the annual stipend has risen to $70,000 per year — a roughly 60% increase — for a total potential award of $210,000 over three years. Payments flow directly to the sponsoring institution as salary support only; benefits, indirect costs, and overhead are excluded.

The Foundation awards 6 to 8 new fellowships annually (7 planned for 2026), making it one of California's more concentrated fellowship funders relative to its asset base. Grantee data spanning multiple years shows $5.08 million distributed across 96 individual fellowship payments, all within California. Stanford University School of Medicine leads with $2.17 million across 38 grant entries (42.7% of the tracked total), followed by UCSF at $796,000 (15.7%), UC San Diego at $665,000 (13.1%), UCLA David Geffen School of Medicine at $442,000 (8.7%), UC Davis at $292,000 (5.7%), USC Keck at $233,000 (4.6%), and UC Irvine at $170,000 (3.3%).

A small secondary giving stream exists: the A.P. Giannini Middle School PTA in San Francisco has received $35,000 across 5 grants for a student award program — a community tribute to the foundation's namesake but negligible in scale at under 1% of total giving. Net investment income is the primary revenue source ($933,000 in 2023), and officer compensation is $0 across all years on record, indicating a lean all-volunteer governance model.

The A.P. Giannini Foundation occupies a specialized niche among postdoctoral biomedical fellowship funders: California-only, open to MD, MD/PhD, and PhD researchers, with a structured leadership development program layered atop the research stipend. The table below compares it to peer funders frequently mentioned in its fellows' career trajectories.

A.P. Giannini is deliberately smaller and more intimate than national peers like the Burroughs Wellcome Fund or HHMI, which translates into a cohort-based community experience — fellows from multiple years interact regularly at retreats and events, and the alumni network is close-knit. Unlike the Damon Runyon Cancer Research Foundation, which restricts to cancer, A.P. Giannini supports broad biomedical research with disease-translation relevance, giving applicants more flexibility in topic. The California-only eligibility significantly concentrates competition among the state's top medical schools rather than drawing nationally, making institutional prestige within California a meaningful factor in the applicant pool.

The Foundation has been active across governance, alumni recognition, and programming in 2025 and 2026. The most significant governance event was the Fall 2025 passing of Anne McWilliams, emeritus trustee and granddaughter of A.P. Giannini himself — the last board member with a direct family connection to the founder. Her death marks a generational milestone in the Foundation's institutional history. Earlier in 2024, medical device industry leader Keith Grossman joined the board, bringing a translational-industry perspective, while a senior board member with more than 40 years of service retired (Summer 2024).

On the alumni and program side, the Winter 2025 newsletter highlighted multiple alumni earning HHMI Hrabowski Scholars Awards, and the Fall 2025 newsletter featured a 2023 fellow winning a Burroughs-Wellcome Award for neuroprosthesis research. The Spring 2026 newsletter reported that 2025 fellows completed their communications training cohort and that a Scientific Advisory Committee member attended the Nobel Prize Ceremony — a signal of the Committee's caliber. The Summer 2026 newsletter announced a former fellow co-founding a cancer therapy start-up and a current fellow's lupus research receiving recognition.

Programmatically, the Foundation expanded its social media presence (Summer 2025) and in Summer 2026 piloted a new virtual series specifically addressing career transitions, indicating growing attention to non-traditional career pathways. The 2026 cycle will fund 7 new fellowships at the current $70,000/year stipend rate, with finalist interviews scheduled for March 5, 2026, at Pebble Beach. No changes to eligibility criteria, geographic scope, or the California-only restriction have been announced.

The Foundation's Scientific Advisory Committee assigns equal weight to four criteria: candidate potential, scientific innovation and medical significance, mentorship quality, and leadership development plan. Applications that excel at science but treat the leadership section as an afterthought will not advance — the 'Leadership Award' designation is substantive, not ceremonial.

Register in the application portal (my.reviewr.com) well ahead of the November 6 deadline. The system sends automated notifications to your three references and your mentor only after you register; late registration compresses the time they have to complete their letters. All materials — including every letter — must be in the portal by 3:00 PM PST on the deadline date. Email and mail submissions are not accepted under any circumstances.

For the research application, the six-component PDF should be assembled in order: biosketch and bibliography (exclude poster presentations and conference abstracts), a 1-page personal statement, a 300-word non-technical summary, a 1-page research significance statement for a general audience, a 5-page single-spaced technical research statement (minimum 12-point font), and the mentor's NIH biosketch with up to 15 publications, current funding, and former trainee placement records. Do not exceed page limits — reviewers notice.

The technical research statement must demonstrate translational relevance. The Foundation explicitly funds research aimed at 'translation of biomedical science into preventions, treatments, and cures' — purely basic science narratives without a plausible disease pathway are at a disadvantage. Use the non-technical summary and general-audience significance page strategically: these sections directly test science communication, which the Foundation treats as evidence of leadership potential.

For references: MD candidates must include a letter from their Residency Chief or Fellowship Director; PhD candidates must include a letter from their doctoral thesis advisor. The prospective mentor cannot serve as a reference. Choose the remaining references from individuals who have observed your research directly — prestigious names without specific knowledge of your lab work are less valuable than well-briefed colleagues.

If invited to the March Pebble Beach finalist interview, prepare to discuss career vision and leadership philosophy as much as experimental design. Prior fellows have gone on to found start-ups, lead academic departments, and win major career awards — demonstrating awareness of this alumni trajectory and articulating where you see yourself within it is appropriate and expected.